Mesenchymal stem cells for management of rheumatoid arthritis

immune modulation, repair or both?

Sharon Ansboro*, Anke J. Roelofs, Cosimo de Bari

*Corresponding author for this work

Research output: Contribution to journalReview article

22 Citations (Scopus)
6 Downloads (Pure)

Abstract

PURPOSE OF REVIEW: Mesenchymal stromal/stem cells (MSCs) have potent anti-inflammatory and immunomodulatory properties, in addition to their ability to form cartilage and bone. The purpose of this review is to highlight recent developments and current knowledge gaps in our understanding of the protective effects of MSCs against inflammatory arthritis, and to discuss their clinical exploitation for the treatment of rheumatoid arthritis (RA). RECENT FINDINGS: The weight of evidence for protective mechanisms of exogenously administered MSCs is on immunomodulatory effects, including inhibition of dendritic cell maturation, polarization of macrophages to an anti-inflammatory phenotype, and activation of regulatory T cells, thereby dampening inflammation and preventing joint damage. Evidence for direct effects on tissue repair is scant. Recent studies have identified MSC subsets in vivo and an important question is whether MSCs in their native tissues have similar immunoregulatory functions. Recent proof-of-concept clinical studies have shown a satisfactory safety profile of allogeneic MSC therapy in RA patients with promising trends for clinical efficacy. SUMMARY: Allogeneic MSCs could be effective in RA. Larger, multicentre clinical studies are needed to provide robust evidence, and MSC treatment at early stages of RA should be explored to ‘reset’ the immune system.

Original languageEnglish
Pages (from-to)201-207
Number of pages7
JournalCurrent Opinion in Rheumatology
Volume29
Issue number2
DOIs
Publication statusPublished - 1 Mar 2017

Fingerprint

Mesenchymal Stromal Cells
Rheumatoid Arthritis
Anti-Inflammatory Agents
Regulatory T-Lymphocytes
Cell- and Tissue-Based Therapy
Dendritic Cells
Multicenter Studies
Arthritis
Cartilage
Immune System

Keywords

  • Mesenchymal Stem/Stromal Cells
  • rheumatoid arthritis
  • immunomodulation
  • cartilage repair

ASJC Scopus subject areas

  • Rheumatology

Cite this

Mesenchymal stem cells for management of rheumatoid arthritis : immune modulation, repair or both? / Ansboro, Sharon; Roelofs, Anke J.; de Bari, Cosimo.

In: Current Opinion in Rheumatology, Vol. 29, No. 2, 01.03.2017, p. 201-207.

Research output: Contribution to journalReview article

@article{f4a0734e8afc43e8af168e59aee7a99f,
title = "Mesenchymal stem cells for management of rheumatoid arthritis: immune modulation, repair or both?",
abstract = "PURPOSE OF REVIEW: Mesenchymal stromal/stem cells (MSCs) have potent anti-inflammatory and immunomodulatory properties, in addition to their ability to form cartilage and bone. The purpose of this review is to highlight recent developments and current knowledge gaps in our understanding of the protective effects of MSCs against inflammatory arthritis, and to discuss their clinical exploitation for the treatment of rheumatoid arthritis (RA). RECENT FINDINGS: The weight of evidence for protective mechanisms of exogenously administered MSCs is on immunomodulatory effects, including inhibition of dendritic cell maturation, polarization of macrophages to an anti-inflammatory phenotype, and activation of regulatory T cells, thereby dampening inflammation and preventing joint damage. Evidence for direct effects on tissue repair is scant. Recent studies have identified MSC subsets in vivo and an important question is whether MSCs in their native tissues have similar immunoregulatory functions. Recent proof-of-concept clinical studies have shown a satisfactory safety profile of allogeneic MSC therapy in RA patients with promising trends for clinical efficacy. SUMMARY: Allogeneic MSCs could be effective in RA. Larger, multicentre clinical studies are needed to provide robust evidence, and MSC treatment at early stages of RA should be explored to ‘reset’ the immune system.",
keywords = "Mesenchymal Stem/Stromal Cells, rheumatoid arthritis, immunomodulation, cartilage repair",
author = "Sharon Ansboro and Roelofs, {Anke J.} and {de Bari}, Cosimo",
note = "The authors are grateful for support to their research from Arthritis Research UK (grants 19271, 19429, 19667, 20050, 20775) and the Medical Research Council (grant no. MR/L020211/1)",
year = "2017",
month = "3",
day = "1",
doi = "10.1097/BOR.0000000000000370",
language = "English",
volume = "29",
pages = "201--207",
journal = "Current Opinion in Rheumatology",
issn = "1040-8711",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Mesenchymal stem cells for management of rheumatoid arthritis

T2 - immune modulation, repair or both?

AU - Ansboro, Sharon

AU - Roelofs, Anke J.

AU - de Bari, Cosimo

N1 - The authors are grateful for support to their research from Arthritis Research UK (grants 19271, 19429, 19667, 20050, 20775) and the Medical Research Council (grant no. MR/L020211/1)

PY - 2017/3/1

Y1 - 2017/3/1

N2 - PURPOSE OF REVIEW: Mesenchymal stromal/stem cells (MSCs) have potent anti-inflammatory and immunomodulatory properties, in addition to their ability to form cartilage and bone. The purpose of this review is to highlight recent developments and current knowledge gaps in our understanding of the protective effects of MSCs against inflammatory arthritis, and to discuss their clinical exploitation for the treatment of rheumatoid arthritis (RA). RECENT FINDINGS: The weight of evidence for protective mechanisms of exogenously administered MSCs is on immunomodulatory effects, including inhibition of dendritic cell maturation, polarization of macrophages to an anti-inflammatory phenotype, and activation of regulatory T cells, thereby dampening inflammation and preventing joint damage. Evidence for direct effects on tissue repair is scant. Recent studies have identified MSC subsets in vivo and an important question is whether MSCs in their native tissues have similar immunoregulatory functions. Recent proof-of-concept clinical studies have shown a satisfactory safety profile of allogeneic MSC therapy in RA patients with promising trends for clinical efficacy. SUMMARY: Allogeneic MSCs could be effective in RA. Larger, multicentre clinical studies are needed to provide robust evidence, and MSC treatment at early stages of RA should be explored to ‘reset’ the immune system.

AB - PURPOSE OF REVIEW: Mesenchymal stromal/stem cells (MSCs) have potent anti-inflammatory and immunomodulatory properties, in addition to their ability to form cartilage and bone. The purpose of this review is to highlight recent developments and current knowledge gaps in our understanding of the protective effects of MSCs against inflammatory arthritis, and to discuss their clinical exploitation for the treatment of rheumatoid arthritis (RA). RECENT FINDINGS: The weight of evidence for protective mechanisms of exogenously administered MSCs is on immunomodulatory effects, including inhibition of dendritic cell maturation, polarization of macrophages to an anti-inflammatory phenotype, and activation of regulatory T cells, thereby dampening inflammation and preventing joint damage. Evidence for direct effects on tissue repair is scant. Recent studies have identified MSC subsets in vivo and an important question is whether MSCs in their native tissues have similar immunoregulatory functions. Recent proof-of-concept clinical studies have shown a satisfactory safety profile of allogeneic MSC therapy in RA patients with promising trends for clinical efficacy. SUMMARY: Allogeneic MSCs could be effective in RA. Larger, multicentre clinical studies are needed to provide robust evidence, and MSC treatment at early stages of RA should be explored to ‘reset’ the immune system.

KW - Mesenchymal Stem/Stromal Cells

KW - rheumatoid arthritis

KW - immunomodulation

KW - cartilage repair

UR - http://www.scopus.com/inward/record.url?scp=85003953006&partnerID=8YFLogxK

U2 - 10.1097/BOR.0000000000000370

DO - 10.1097/BOR.0000000000000370

M3 - Review article

VL - 29

SP - 201

EP - 207

JO - Current Opinion in Rheumatology

JF - Current Opinion in Rheumatology

SN - 1040-8711

IS - 2

ER -